KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sabra Health Care REIT (SBRA) Depreciation & Amortization (CF) (2016 - 2025)

Sabra Health Care REIT (SBRA) has 15 years of Depreciation & Amortization (CF) data on record, last reported at $51.4 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 21.5% year-over-year to $51.4 million; the TTM value through Dec 2025 reached $187.0 million, up 10.24%, while the annual FY2025 figure was $187.0 million, 10.24% up from the prior year.
  • Depreciation & Amortization (CF) reached $51.4 million in Q4 2025 per SBRA's latest filing, up from $48.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $52.8 million in Q1 2023 and bottomed at $41.7 million in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $45.3 million, with a median of $44.4 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 18.77% in 2024, then increased 21.5% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $45.1 million in 2021, then increased by 10.75% to $49.9 million in 2022, then fell by 14.12% to $42.9 million in 2023, then fell by 1.32% to $42.3 million in 2024, then grew by 21.5% to $51.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $51.4 million in Q4 2025, $48.5 million in Q3 2025, and $43.6 million in Q2 2025.